Trial Profile
A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Goserelin (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms NeoPalAna
- 28 Nov 2023 Planned End Date changed from 30 Apr 2027 to 24 Aug 2026.
- 02 May 2019 Planned number of patients changed from 55 to 87.
- 02 May 2019 Planned End Date changed from 30 Apr 2025 to 30 Apr 2027.